Attenuated 5-FU resistance of CD147 knockdown 5FU-R CRC cells was partially be reversed by the glycolytic activators, Mitapivat (a selective PKM2 activator) or Oligomycin (an ATP synthase/complex V inhibitor, could be used to release glycolytic reserve) (Figures S2G, H). The gene discussed is BSG; the disease is colorectal carcinoma.